Navigation Links
Phase III study compared neoadjuvant therapy with lapatinib or trastuzumab for early breast cancer
Date:12/10/2010

SAN ANTONIO Researchers presented Phase III efficacy data from the GeparQuinto study, a head-to-head comparison of neoadjuvant lapatinib and trastuzumab in combination with chemotherapy for patients with early breast cancer, at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12.

"We had a primary goal to compare the standard anti-HER2 neoadjuvant combination of chemotherapy, trastuzumab, with the new combination of chemotherapy and lapatinib," said Michael Untch, M.D., head of the multidisciplinary breast cancer department at Helios Clinic in Berlin, Germany.

The GeparQuinto study was conducted at 85 centers throughout Germany and includes 2,500 patients, 550 of whom have HER2-neu-overexpressing breast cancer. This is the largest prospective patient cohort of chemo-targeted neoadjuvant therapy worldwide.

All patients received four cycles of 90 mg/m2 epirubicin and 600 mg/m2 cyclophosphamide every three weeks, followed by four cycles of 100 mg/m2 docetaxel. They were randomly assigned to also receive concomitant 6 mg/kg trastuzumab every three weeks or 1,250 mg lapatinib per day throughout all cycles.

At baseline, patient characteristics were similar between the two groups, with both groups presenting a clinical median tumor size of 40 mm. The researchers also reported a similar number of patients in each group with T4a-c or T4d disease, bilateral, multifocal or multicentric disease, and estrogen receptor-negative and progesterone receptor-negative disease.

The last of the patients are currently undergoing surgery, and Untch will present histological and surgical outcome results for these patients at the symposium.

"After assessing response to neoadjuvant chemo-targeted therapy in patients with HER2 overexpressing tumors, we are following the patients from this study to see whether pathologic complete response at surgery is correlated to the outcome of the patients," he said.

<
'/>"/>
Contact: Jeremy Moore
jeremy.moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

Page: 1 2

Related biology news :

1. Early safety results promising for Phase I/II trial of gene therapy treatment of hemophilia B
2. PAREXEL Completes 200 Patient Studies In Its Early Phase Units Over Three Years
3. OHSU Doernbecher Childrens Hospital conducts second phase of landmark Batten study
4. Onconova announces FDA agreement of a SPA for a pivotal phase 3 trial of Estybon in MDS
5. First X-ray lasers early success brings approval for next-phase facility
6. ViroPharma Announces Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze(TM) (C1 Esterase Inhibitor [Human])
7. Registration Opens for Next Testing Phase of IEEE Certified Biometrics Professional Program
8. First phase of pan-tropical forest mapping debuting at COP15
9. NIH funds new phase of high school-university research partnership
10. Scientists seek new emphases in Arctic climate change research
11. Resolvyx announces positive data -- Phase 2 trial of resolvin RX-10045 for dry eye syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... collapses from a quantum superposition to a classical state or ... a quantum trajectory. For each start and end state there ... not as easy to predict the path or track it ... our everyday, classical world. , In a new paper featured ... from the Institute for Quantum Studies at Chapman University, the ...
(Date:8/1/2014)... been recorded into the Reptile Database, a web-based ... making the reptile species among the most diverse ... fish species. , For some time, experts have ... reptiles would become the most diverse vertebrate group ... crocodiles, tuataras and amphisbaenians. , "Officially, we have ...
(Date:8/1/2014)... appear in the fossil record about 200,000 years ago, ... making art and advanced tools became widespread. , ... Current Anthropology finds that human skulls changed ... at around the same time that culture was blossoming. ... art and rapid cultural exchange probably came at the ...
Breaking Biology News(10 mins):Mapping the optimal route between two quantum states 2Reptile Database surpasses 10,000 reptile species 2Reptile Database surpasses 10,000 reptile species 3Society bloomed with gentler personalities and more feminine faces 2
... where and how some plant seeds store iron, a valuable ... plants. Their research helps address the worldwide problem of iron ... iron is stored in the developing vascular system of the ... particular, iron is stored in the vacuole, a plant cell's ...
... evaluated improvements in the end-of-life care in intensive care ... special supplement to Critical Care Medicine, the journal of ... dedicated entirely to end-of-life care in the critical care ... critically ill and dying patients in the ICU remains ...
... factor known to be important for the survival of ... motor neurons ?critical brain cells that connect the cerebral ... motor neuron diseases like amyotrophic lateral sclerosis (ALS or ... of Nature Neuroscience, two investigators from Massachusetts General Hospital ...
Cached Biology News:Plant studies reveal how, where seeds store iron 2End-of-life care can be improved 2End-of-life care can be improved 3Growth factor stimulates rapid extension of key motor neurons in brain 2
(Date:8/1/2014)... is the photonic analog of topological electron flow in ... flows around the edge of the material but not ... even if electrons encounter impurities in the material the ... In the photonic equivalent, light ... in a meta-material consisting of an array of tiny ...
(Date:8/1/2014)... LA (PRWEB) August 01, 2014 Chantel Lee ... conduct research for 10 40-hour weeks with Dr. Juan Rodriguez, ... of diabetic retinopathy, a common diabetic eye disease caused by ... , "What Chantel and Eli accomplished is quite remarkable,” said ... only a concept when they started, and together carried it ...
(Date:8/1/2014)... Stony Brook, NY (PRWEB) August 01, 2014 ... (Twitter: @APDN), a provider of DNA-based anti-counterfeiting technology and ... Tuesday August 12, 2014 to discuss its fiscal third ... be filed with the SEC by the end of ... Applied DNA Sciences, Inc. management will host a conference ...
(Date:8/1/2014)... 2014 This is a professional and ... Bicarbonate industry in Global and China. The report provides ... and industry chain structure. Global market analysis and Chinese ... history, developments, trends and competitive landscape of the market. ... also offered. , The report also focuses on development ...
Breaking Biology Technology:On-chip topological light 2On-chip topological light 3Two Centenary College Students Tackle Diabetic Retinopathy Research 2Applied DNA Sciences to Host Conference Call Tuesday August 12, 2014 2Applied DNA Sciences to Host Conference Call Tuesday August 12, 2014 3Ammonium Bicarbonate Market in Internations & Chinese Regions Research Analysis Now Available at DeepResearchReports.com 2Ammonium Bicarbonate Market in Internations & Chinese Regions Research Analysis Now Available at DeepResearchReports.com 3
... awards recognize outstanding journalism demonstrating the essential role ... , , ... 16 The Foundation for Biomedical Research (FBR) today announces the ... named in honor of FBR,s late chairman Dr. Michael E. DeBakey ...
... , AKRON, Ohio , June 16 On Wednesday, ... Ohio promises to inspire renewed hope for new jobs in ... coatings industries will share their insight on innovation, global commerce and the new ... at www.ohio.com/jobgrowth . , , ...
... and SAN DIEGO , June 16 ... Biosciences, Inc. (Nasdaq: NBIX ) today announced that ... and commercialize elagolix for the treatment of endometriosis-related pain. ... antagonist, which has recently completed a phase IIb study ...
Cached Biology Technology:2010 Michael E. DeBakey Journalism Awards Announced 2Free Web Cast On Fueling Ohio's New Job Growth 2Abbott and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolix for the Treatment of Endometriosis 2Abbott and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolix for the Treatment of Endometriosis 3Abbott and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolix for the Treatment of Endometriosis 4Abbott and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolix for the Treatment of Endometriosis 5
Applications include ELISA, immunochemistry, and Western blotting. Working Concentrations: ELISA: 0.005-0.05 U/ml, immunohisto/cytochemistry: 0.25-0.5 U/ml, Western blot: 0.1-0.25 U/ml....
Poly A Polymerase catalyzes the addition of AMP to the 3' hydroxyl terminus of RNA. Poly A Polymerase can add poly(C) and poly(U) to RNA but does so with much-reduced efficiency....
... a unique β-agarose digesting enzyme developed at ... DNA and RNA from low melting point ... TBE, MOPS, or phosphate buffers. The gel ... TBE, MOPS, and phosphate electrophoresis buffers or ...
Recombinant Cat Interferon Alpha Activity: 2.7 x 10 7 u/mg...
Biology Products: